MHC class i antigen processing and presenting machinery: Organization, function, and defects in tumor cells

Journal of the National Cancer Institute

Volumn 105, Issue 16, 2013, Pages 1172-1187

  Leone, Patrizia ^a   Shin, Eui Cheol ^b   Perosa, Federico ^a   Vacca, Angelo ^a   Dammacco, Franco ^a   Racanelli, Vito ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^b Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; AMINOPEPTIDASE; CALNEXIN; CALRETICULIN; CELL PROTEIN; CHAPERONE; DIPEPTIDASE; GAMMA UROGASTRONE; HLA A11 ANTIGEN; HLA A3 ANTIGEN; HLA ANTIGEN CLASS 1; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2; INTERFERON REGULATORY FACTOR 1; JANUS KINASE 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELAN A; PROTEASOME; STAT1 PROTEIN; T LYMPHOCYTE RECEPTOR; TAPASIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR 1; TRANSCRIPTION FACTOR E2F; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 1; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADAPTIVE IMMUNITY; ANTIGEN PRESENTATION; ANTIGEN PROCESSING MACHINERY; ASTROCYTOMA; BLADDER CARCINOMA; BREAST CANCER; BREAST CARCINOMA; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; COLORECTAL CARCINOMA; ENDOPLASMIC RETICULUM; ENZYMATIC DEGRADATION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CARCINOMA; FRAMESHIFT MUTATION; GENE MUTATION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HETEROZYGOSITY LOSS; HUMAN; KIDNEY CARCINOMA; LARYNX CARCINOMA; LUNG CARCINOMA; MAXILLA SINUS CARCINOMA; MEDULLOBLASTOMA; MELANOMA; MONOCLONAL IMMUNOGLOBULINEMIA; MOUTH SQUAMOUS CELL CARCINOMA; MULTIPLE MYELOMA; NEUROBLASTOMA; NONHUMAN; OVARY CARCINOMA; PANCREAS ADENOCARCINOMA; POINT MUTATION; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CARCINOMA; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SUBUNIT; PROTEIN TRANSPORT; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SQUAMOUS CELL CARCINOMA; STOMACH ADENOCARCINOMA; STOMACH CARCINOMA; T LYMPHOCYTE; TUMOR CELL; TUMOR ESCAPE; UTERINE CERVIX CARCINOMA;

AMINOPEPTIDASES; ANIMALS; ANTIGEN PRESENTATION; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT, ACTIVE; CD8-POSITIVE T-LYMPHOCYTES; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; MEMBRANE TRANSPORT PROTEINS; MOLECULAR CHAPERONES; NEOPLASMS; PEPTIDES; PROTEASOME ENDOPEPTIDASE COMPLEX;

EID: 84883157468     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt184     Document Type: Review

References (209)

1. Ciechanover A. Intracellular protein degradation: from a vague idea thru the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting. Biochim Biophys Acta. 2012;1824(1):3-13.
2. Watts C. The endosome-lysosome pathway and information generation in the immune system. Biochim Biophys Acta. 2012;1824(1):14-21.
3. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteo-lytic pathway: destruction for the sake of construction. Physiol Rev. 2002;82(2):373-428.
4. Goldberg AL. Protein degradation and protection against misfolded or damaged proteins. Nature. 2003;426(6968):895-899.
5. Schubert U, Anton LC, Gibbs J, Norbury CC, Yewdell JW, Bennink JR. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature. 2000;404(6779):770-774.
6. Yewdell JW, Schubert U, Bennink JR. At the crossroads of cell biology and immunology: DRiPs and other sources of peptide ligands for MHC class I molecules. J Cell Sci. 2001;114(Pt 5):845-851.
7. Yewdell JW. Not such a dismal science: the economics of protein synthesis, folding, degradation and antigen processing. Trends Cell Biol. 2001;11(7):294-297.
8. Joffre O P, Segura E, Savina A, Amigorena S. Cross-presentation by dendritic cells. Nat Rev Immunol. 2012;12(8):557-569.
9. Thielens A, Vivier E, Romagne F. NK cell MHC class I specific receptors (KIR): from biology to clinical intervention. Curr Opin Immunol. 2012;24(2):239-245.
10. Koegl M, Hoppe T, Schlenker S, Ulrich HD, Mayer TU, Jentsch S. A novel ubiquitination factor, E4, is involved in multiubiquitin chain assembly. Cell. 1999;96(5):635-644.
11. Antoniou AN, Powis SJ, Elliott T. Assembly and export of MHC class I peptide ligands. Curr Opin Immunol. 2003;15(1):75-81.
12. Jensen PE. Recent advances in antigen processing and presentation. Nat Immunol. 2007;8(10):1041-1048.
13. Kloetzel PM. Antigen processing by the proteasome. Nat Rev Mol Cell Biol. 2001;2(3):179-187.
14. Sant A, Yewdell J. Antigen processing and recognition. Curr Opin Immunol. 2003;15(1):66-68.
15. Yewdell JW. The seven dirty little secrets of major histocompatibility complex class I antigen processing. Immunol Rev. 2005;207:8-18.
16. Goldberg AL. Functions of the proteasome: the lysis at the end of the tunnel. Science. 1995;268(5210):522-523.
17. Kloetzel PM. The proteasome and MHC class I antigen processing. Biochim Biophys Acta. 2004;1695(1-3):225-233.
18. Rechsteiner M, Hoffman L, Dubiel W. The multicatalytic and 26 S proteases. J Biol Chem. 1993;268(9):6065-6068.
19. Dick TP, Nussbaum AK, Deeg M, et al. Contribution of proteasomal beta-subunits to the cleavage of peptide substrates analyzed with yeast mutants. J Biol Chem. 1998;273(40):25637-25646.
20. Heinemeyer W, Fischer M, Krimmer T, Stachon U, Wolf DH. The active sites of the eukaryotic 20 S proteasome and their involvement in subunit precursor processing. J Biol Chem. 1997;272(40):25200-25209.
21. Groll M, Bajorek M, Kohler A, et al. A gated channel into the proteasome core particle. Nat Struct Biol. 2000;7(11):1062-1067.
22. Voges D, Zwickl P, Baumeister W. The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu Rev Biochem. 1999;68:1015-1068.
23. Glickman MH, Rubin DM, Fu H, et al. Functional analysis of the protea-some regulatory particle. Mol Biol Rep. 1999;26(1-2):21-28.
24. Braun BC, Glickman M, Kraft R, et al. The base of the protea-some regulatory particle exhibits chaperone-like activity. Nat Cell Biol. 1999;1(4):221-226.
25. Strickland E, Hakala K, Thomas PJ, DeMartino GN. Recognition of mis-folding proteins by PA700, the regulatory subcomplex of the 26 S protea-some. J Biol Chem. 2000;275(8):5565-5572.
26. Hill C P, Masters EI, Whitby FG. The 11S regulators of 20S proteasome activity. Curr To p Microbiol Immunol. 2002;268:73-89.
27. Ustrell V, Hoffman L, Pratt G, Rechsteiner M. PA200, a nuclear pro-teasome activator involved in DNA repair. EMBO J. 2002;21(13): 3516-3525.
28. Cutchen-Maloney SL, Matsuda K, Shimbara N, et al. cDNA cloning, expression, and functional characterization of PI31, a proline-rich inhibitor of the proteasome. J Biol Chem. 2000;275(24):18557-18565.
29. Zaiss DM, Standera S, Holzhutter H, Kloetzel P, Sijts AJ. The proteasome inhibitor PI31 competes with PA28 for binding to 20S proteasomes. FEBS Lett. 1999;457(3):333-338.
30. Whitby FG, Masters EI, Kramer L, et al. Structural basis for the activation of 20S proteasomes by 11S regulators. Nature. 2000;408(6808):115-120.
31. Griffin TA, Nandi D, Cruz M, et al. Immunoproteasome assembly: cooperative incorporation of interferon gamma (IFN-gamma)-inducible subu-nits. J Exp Med. 1998;187(1):97-104.
32. Groettrup M, Standera S, Stohwasser R, Kloetzel PM. The subunits MECL-1 and LMP2 are mutually required for incorporation into the 20S proteasome. Proc Natl Acad Sci USA. 1997;94(17):8970-8975.
33. Nandi D, Woodward E, Ginsburg DB, Monaco JJ. Intermediates in the formation of mouse 20S proteasomes: implications for the assembly of precursor beta subunits. EMBO J. 1997;16(17):5363-5375.
34. Aki M, Shimbara N, Takashina M, et al. Interferon-gamma induces different subunit organizations and functional diversity of proteasomes. J Biochem. 1994;115(2):257-269.
35. Shin EC, Seifert U, Kato T, et al. Virus-induced type I IFN stimulates generation of immunoproteasomes at the site of infection. J Clin Invest. 2006;116(11):3006-3014.
36. Stohwasser R, Standera S, Peters I, Kloetzel PM, Groettrup M. Molecular cloning of the mouse proteasome subunits MC14 and MECL-1: reciprocally regulated tissue expression of interferon-gamma-modulated proteasome subunits. Eur J Immunol. 1997;27(5):1182-1187.
37. Macagno A, Gilliet M, Sallusto F, Lanzavecchia A, Nestle FO, Groettrup M. Dendritic cells up-regulate immunoproteasomes and the proteasome regulator PA28 during maturation. Eur J Immunol. 1999;29(12):4037-4042.
38. Gaczynska M, Rock KL, Spies T, Goldberg AL. Peptidase activities of proteasomes are differentially regulated by the major histocompatibility complex-encoded genes for LMP2 and LMP7. Proc Natl Acad Sci USA. 1994;91(20):9213-9217.
39. Toes RE, Nussbaum AK, Degermann S, et al. Discrete cleavage motifs of constitutive and immunoproteasomes revealed by quantitative analysis of cleavage products. J Exp Med. 2001;194(1):1-12.
40. Chen W, Norbury CC, Cho Y, Yewdell JW, Bennink JR. Immuno-proteasomes shape immunodominance hierarchies of antiviral CD8(+) T cells at the levels of T cell repertoire and presentation of viral antigens. J Exp Med. 2001;193(11):1319-1326.
41. Melnikova VI, Sharova N P, Maslova EV, Voronova SN, Zakharova LA. Ontogenesis of rat immune system: proteasome expression in different cell populations of the developing thymus. Cell Immunol. 2010;266(1):83-89.
42. Singh S, Awasthi N, Egwuagu CE, Wagner BJ. Immunoproteasome expression in a nonimmune tissue, the ocular lens. Arch Biochem Biophys. 2002;405(2):147-153.
43. Sijts AJ, Ruppert T, Rehermann B, Schmidt M, Koszinowski U, Kloetzel PM. Efficient generation of a hepatitis B virus cytotoxic T lymphocyte epitope requires the structural features of immunoproteasomes. J Exp Med. 2000;191(3):503-514.
44. Kincaid EZ, Che JW, York I, et al. Mice completely lacking immuno-proteasomes show major changes in antigen presentation. Nat Immunol. 2012;13(2):129-135.
45. Craiu A, Akopian T, Goldberg A, Rock KL. Tw o distinct proteolytic processes in the generation of a major histocompatibility complex class I-presented peptide. Proc Natl Acad Sci USA. 1997;94(20):10850-10855.
46. Hammer GE, Kanaseki T, Shastri N. The final touches make perfect the peptide-MHC class I repertoire. Immunity. 2007;26(4):397-406.
47. Reits E, Griekspoor A, Neijssen J, et al. Peptide diffusion, protection, and degradation in nuclear and cytoplasmic compartments before antigen presentation by MHC class I. Immunity. 2003;18(1):97-108.
48. Benham AM, Gromme M, Neefjes J. Allelic differences in the relationship between proteasome activity and MHC class I peptide loading. J Immunol. 1998;161(1):83-89.
49. Geier E, Pfeifer G, Wilm M, et al. A giant protease with potential to substitute for some functions of the proteasome. Science. 1999;283(5404):978- 981.
50. Seifert U, Maranon C, Shmueli A, et al. An essential role for tripeptidyl peptidase in the generation of an MHC class I epitope. Nat Immunol. 2003;4(4):375-379.
51. Parmentier N, Stroobant V, Colau D, de DP, Morel S, Chapiro J, et al. Production of an antigenic peptide by insulin-degrading enzyme. Nat Immunol. 2010;11(5):449-454.
52. Caballero OL, Chen YT. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci. 2009;100(11):2014-2021.
53. Kessler JH, Khan S, Seifert U, et al. Antigen processing by nardilysin and thimet oligopeptidase generates cytotoxic T cell epitopes. Nat Immunol. 2011;12(1):45-53.
54. Brouwenstijn N, Serwold T, Shastri N. MHC class I molecules can direct proteolytic cleavage of antigenic precursors in the endoplasmic reticulum. Immunity. 2001;15(1):95-104.
55. Fruci D, Niedermann G, Butler RH, van Endert PM. Efficient MHC class I-independent amino-terminal trimming of epitope precursor pep-tides in the endoplasmic reticulum. Immunity. 2001;15(3):467-476.
56. Chang SC, Momburg F, Bhutani N, Goldberg AL. The ER aminopeptidase, ERAP1, trims precursors to lengths of MHC class I peptides by a "molecular ruler" mechanism. Proc Natl Acad Sci USA. 2005;102(47):17107-17112.
57. Shin EC, Seifert U, Urban S, et al. Proteasome activator and antigen-processing aminopeptidases are regulated by virus-induced type I inter-feron in the hepatitis C virus-infected liver. J Interferon Cytokine Res. 2007;27(12):985-990.
58. Shen XZ, Billet S, Lin C, et al. The carboxypeptidase ACE shapes the MHC class I peptide repertoire. Nat Immunol. 2011;12(11):1078-1085.
59. Schmitt L, Tampe R. Structure and mechanism of ABC transporters. Curr Opin Struct Biol. 2002;12(6):754-60.
60. Arora S, Lapinski PE, Raghavan M. Use of chimeric proteins to investigate the role of transporter associated with antigen processing (TAP) structural domains in peptide binding and translocation. Proc Natl Acad Sci USA. 2001;98(13):7241-7246.
61. Higgins CF, Linton KJ. The ATP switch model for ABC transporters. Nat Struct Mol Biol. 2004;11(10):918-926.
62. Parcej D, Tampe R. ABC proteins in antigen translocation and viral inhibition. Nat Chem Biol. 2010;6(8):572-580.
63. Herget M, Baldauf C, Scholz C, et al. Conformation of peptides bound to the transporter associated with antigen processing (TAP). Proc Natl Acad Sci USA. 2011;108(4):1349-1354.
64. Koopmann JO, Post M, Neefjes JJ, Hammerling GJ, Momburg F. Translocation of long peptides by transporters associated with antigen processing (TAP). Eur J Immunol. 1996;26(8):1720-1728.
65. Momburg F, Roelse J, Howard JC, Butcher GW, Hammerling GJ, Neefjes JJ. Selectivity of MHC-encoded peptide transporters from human, mouse and rat. Nature. 1994;367(6464):648-651.
66. Momburg F, Roelse J, Hammerling GJ, Neefjes JJ. Peptide size selection by the major histocompatibility complex-encoded peptide transporter. J Exp Med. 1994;179(5):1613-1623.
67. Momburg F, Hammerling GJ. Generation and TAP-mediated transport of peptides for major histocompatibility complex class I molecules. Adv Immunol. 1998;68:191-256.
68. Schumacher TN, Kantesaria DV, Heemels MT, shton-Rickardt PG, Shepherd JC, Fruh K, et al. Peptide length and sequence specificity of the mouse TAP1/TAP2 translocator. J Exp Med. 1994;179(2):533-540.
69. Roelse J, Gromme M, Momburg F, Hammerling G, Neefjes J. Trimming of TAP-translocated peptides in the endoplasmic reticulum and in the cytosol during recycling. J Exp Med. 1994;180(5):1591-1597.
70. Diedrich G, Bangia N, Pan M, Cresswell P. A role for calnexin in the assembly of the MHC class I loading complex in the endoplasmic reticu-lum. J Immunol. 2001;166(3):1703-179.
71. Hughes EA, Cresswell P. The thiol oxidoreductase ERp57 is a component of the MHC class I peptide-loading complex. Curr Biol. 1998;8(12):709-712.
72. Morrice NA, Powis SJ. A role for the thiol-dependent reductase ERp57 in the assembly of MHC class I molecules. Curr Biol. 1998;8(12):713-76.
73. Sadasivan B, Lehner PJ, Ortmann B, Spies T, Cresswell P. Roles for cal-reticulin and a novel glycoprotein, tapasin, in the interaction of MHC class I molecules with TAP. Immunity. 1996;5(2):103-114.
74. Momburg F, Tan P. Tapasin-the keystone of the loading complex optimizing peptide binding by MHC class I molecules in the endoplasmic reticu-lum. Mol Immunol. 2002;39(3-4):217-233.
75. Ortmann B, Copeman J, Lehner PJ, et al. A critical role for tapasin in the assembly and function of multimeric MHC class I-TAP complexes. Science. 1997;277(5330):1306-1309.
76. Dick T P, Bangia N, Peaper DR, Cresswell P. Disulfide bond isomeriza-tion and the assembly of MHC class I-peptide complexes. Immunity. 2002;16(1):87-98.
77. Ortmann B, Androlewicz MJ, Cresswell P. MHC class I/beta 2-microglob-ulin complexes associate with TAP transporters before peptide binding. Nature. 1994;368(6474):864-867.
78. Wright CA, Kozik P, Zacharias M, Springer S. Tapasin and other chaperones: models of the MHC class I loading complex. Biol Chem. 2004;385(9):763-778.
79. Hammond C, Braakman I, Helenius A. Role of N-linked oligosaccharide recognition, glucose trimming, and calnexin in glycoprotein folding and quality control. Proc Natl Acad Sci USA. 1994;91(3):913-917.
80. Wada I, Imai S, Kai M, Sakane F, Kanoh H. Chaperone function of cal-reticulin when expressed in the endoplasmic reticulum as the membrane-anchored and soluble forms. J Biol Chem. 1995;270(35):20298-20304.
81. Oliver JD, Roderick HL, Llewellyn DH, High S. ERp57 functions as a subunit of specific complexes formed with the ER lectins calreticulin and calnexin. Mol Biol Cell. 1999;10(8):2573-2582.
82. Ellgaard L, Helenius A. ER quality control: towards an understanding at the molecular level. Curr Opin Cell Biol. 2001;13(4):431-437.
83. Degen E, Cohen-Doyle MF, Williams DB. Efficient dissociation of the p88 chaperone from major histocompatibility complex class I molecules requires both beta 2-microglobulin and peptide. J Exp Med. 1992;175(6):1653-1661.
84. Nossner E, Parham P. Species-specific differences in chaperone interaction of human and mouse major histocompatibility complex class I molecules. J Exp Med. 1995;181(1):327-337.
85. Lehner PJ, Surman MJ, Cresswell P. Soluble tapasin restores MHC class I expression and function in the tapasin-negative cell line.220. Immunity. 1998;8(2):221-231.
86. Grandea AG, III, Lehner PJ, Cresswell P, Spies T. Regulation of MHC class I heterodimer stability and interaction with TAP by tapasin. Immunogenetics. 1997;46(6):477-483.
87. Williams AP, Peh CA, Purcell AW, McCluskey J, Elliott T. Optimization of the MHC class I peptide cargo is dependent on tapasin. Immunity. 2002;16(4):509-520.
88. Kloor M, Becker C, Benner A, et al. Immunoselective pressure and human leukocyte antigen class I antigen machinery defects in microsatellite unstable colorectal cancers. Cancer Res. 2005;65(14):6418-6424.
89. Cathro H P, Smolkin ME, Theodorescu D, Jo VY, Ferrone S, Frierson HF Jr. Relationship between HLA class I antigen processing machinery component expression and the clinicopathologic characteristics of bladder carcinomas. Cancer Immunol Immunother. 2010;59(3):465-472.
90. Leffers N, Gooden MJ, Mokhova AA, et al. Down-regulation of protea-somal subunit MB1 is an independent predictor of improved survival in ovarian cancer. Gynecol Oncol. 2009;113(2):256-263.
91. Raffaghello L, Nozza P, Morandi F, et al. Expression and functional analysis of human leukocyte antigen class I antigen-processing machinery in medulloblastoma. Cancer Res. 2007;67(11):5471-5478.
92. Hoves S, Aigner M, Pfeiffer C, Laumer M, Obermann EC, Mackensen A. In situ analysis of the antigen-processing machinery in acute myeloid leukaemic blasts by tissue microarray. Leukemia. 2009;23(5):877-85.
93. Meissner M, Reichert TE, Kunkel M, et al. Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squa-mous cell carcinoma: association with clinical outcome. Clin Cancer Res. 2005;11(7):2552-2560.
94. Ogino T, Shigyo H, Ishii H, et al. HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker. Cancer Res. 2006;66(18):9281-9289.
95. Liu Q, Hao C, Su P, Shi J. Down-regulation of HLA class I antigen-processing machinery components in esophageal squamous cell carcinomas: association with disease progression. Scand J Gastroenterol. 2009;44(8):960-969.
96. Qifeng S, Bo C, Xingtao J, Chuanliang P, Xiaogang Z. Methylation of the promoter of human leukocyte antigen class I in human esophageal squa-mous cell carcinoma and its histopathological characteristics. J Thorac Cardiovasc Surg. 2011;141(3):808-814.
97. Ayshamgul H, Ma H, Ilyar S, Zhang LW, Abulizi A. Association of defective HLA-I expression with antigen processing machinery and their association with clinicopathological characteristics in Kazak patients with esophageal cancer. Chin Med J (Engl). 2011;124(3):341-346.
98. Hirata T, Yamamoto H, Taniguchi H, et al. Characterization of the immune escape phenotype of human gastric cancers with and without high-frequency microsatellite instability. J Pathol. 2007;211(5):516-523.
99. Atkins D, Breuckmann A, Schmahl GE, et al. MHC class I antigen processing pathway defects, ras mutations and disease stage in colorectal carcinoma. Int J Cancer. 2004;109(2):265-273.
100. Dierssen JW, de Miranda NF, Ferrone S, et al. HNPCC versus sporadic microsatellite-unstable colon cancers follow different routes toward loss of HLA class I expression. BMC Cancer. 2007;7:33.
101. Atkins D, Ferrone S, Schmahl GE, Storkel S, Seliger B. Down-regulation of HLA class I antigen processing molecules: an immune escape mechanism of renal cell carcinoma? J Urol. 2004;171(2 Pt 1):885-889.
102. Seliger B, Atkins D, Bock M, et al. Characterization of human lymphocyte antigen class I antigen-processing machinery defects in renal cell carcinoma lesions with special emphasis on transporter-associated with antigen-processing down-regulation. Clin Cancer Res. 2003;9(5):1721-1727.
103. Romero JM, Jimenez P, Cabrera T, et al. Coordinated downregulation of the antigen presentation machinery and HLA class I/beta2-microglobulin complex is responsible for HLA-ABC loss in bladder cancer. Int J Cancer. 2005;113(4):605-610.
104. Seliger B, Stoehr R, Handke D, et al. Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer. Cancer Immunol Immunother. 2010;59(4):529-540.
105. Hasim A, Abudula M, Aimiduo R, et al. Post-transcriptional and epi-genetic regulation of antigen processing machinery (APM) components and HLA-I in cervical cancers from Uighur women. PLoS One. 2012;7(9):e44952.
106. Mehta AM, Jordanova ES, Kenter GG, Ferrone S, Fleuren GJ. Association of antigen processing machinery and HLA class I defects with clinico-pathological outcome in cervical carcinoma. Cancer Immunol Immunother. 2008;57(2):197-206.
107. Gobbi G, Mirandola P, Micheloni C, et al. Expression of HLA class I antigen and proteasome subunits LMP-2 and LMP-10 in primary vs. meta-static breast carcinoma lesions. Int J Oncol. 2004;25(6):1625-1629.
108. Liu Y, Komohara Y, Domenick N, et al. Expression of antigen processing and presenting molecules in brain metastasis of breast cancer. Cancer Immunol Immunother. 2012;61(6):789-801.
109. Mehling M, Simon P, Mittelbronn M, et al. WHO grade associated down-regulation of MHC class I antigen-processing machinery components in human astrocytomas: does it reflect a potential immune escape mechanism? Acta Neuropathol. 2007;114(2):111-119.
110. Raffaghello L, Prigione I, Bocca P, et al. Multiple defects of the antigen-processing machinery components in human neuroblastoma: immuno-therapeutic implications. Oncogene. 2005;24(29):4634-4644.
111. Kageshita T, Hirai S, Ono T, Hicklin DJ, Ferrone S. Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. Am J Pathol. 1999;154(3):745-754.
112. Kamarashev J, Ferrone S, Seifert B, et al. TAP1 down-regulation in primary melanoma lesions: an independent marker of poor prognosis. Int J Cancer. 2001;95(1):23-28.
113. Racanelli V, Leone P, Frassanito MA, et al. Alterations in the antigen processing-presenting machinery of transformed plasma cells are associated with reduced recognition by CD8+ T cells and characterize the progression of MGUS to multiple myeloma. Blood. 2010;115(6):1185-1193.
114. Mehta AM, Jordanova ES, van Wezel T, et al. Genetic variation of antigen processing machinery components and association with cervical carcinoma. Genes Chromosomes Cancer. 2007;46(6):577-586.
115. Dovhey SE, Ghosh NS, Wright KL. Loss of interferon-gamma induc-ibility of TAP1 and LMP2 in a renal cell carcinoma cell line. Cancer Res. 2000;60(20):5789-5796.
116. Respa A, Bukur J, Ferrone S, et al. Association of IFN-gamma signal trans-duction defects with impaired HLA class I antigen processing in melanoma cell lines. Clin Cancer Res. 2011;17(9):2668-2678.
117. Bandoh N, Ogino T, Katayama A, et al. HLA class I antigen and transporter associated with antigen processing downregulation in metastatic lesions of head and neck squamous cell carcinoma as a marker of poor prognosis. Oncol Rep. 2010;23(4):933-939.
118. Feenstra M, Veltkamp M, van Kuik J, et al. HLA class I expression and chromosomal deletions at 6p and 15q in head and neck squamous cell carcinomas. Tissue Antigens. 1999;54(3):235-245.
119. Lopez-Albaitero A, Nayak JV, Ogino T, et al. Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL. J Immunol. 2006;176(6):3402-3409.
120. Milano F, Guarriera M, Rygiel AM, Krishnadath KK. Trastuzumab mediated T-cell response against HER-2/neu overexpressing esophageal ade-nocarcinoma depends on intact antigen processing machinery. PLoS One. 2010;5(8):e12424.
121. Pandha H, Rigg A, John J, Lemoine N. Loss of expression of antigen-presenting molecules in human pancreatic cancer and pancreatic cancer cell lines. Clin Exp Immunol. 2007;148(1):127-135.
122. de Miranda NF, Nielsen M, Pereira D, et al. MUTYH-associated polyposis carcinomas frequently lose HLA class I expression-a common event amongst DNA-repair-deficient colorectal cancers. J Pathol. 2009;219(1):69-76.
123. Kaklamanis L, Townsend A, Doussis-Anagnostopoulou IA, Mortensen N, Harris AL, Gatter KC. Loss of major histocompatibility complex-encoded transporter associated with antigen presentation (TAP) in colorectal cancer. Am J Pathol. 1994;145(3):505-509.
124. Kasajima A, Sers C, Sasano H, et al. Down-regulation of the antigen processing machinery is linked to a loss of inflammatory response in colorectal cancer. Hum Pathol. 2010;41(12):1758-1769.
125. Alimonti J, Zhang QJ, Gabathuler R, Reid G, Chen SS, Jefferies WA. TAP expression provides a general method for improving the recognition of malignant cells in vivo. Nat Biotechnol. 2000;18(5):515-20.
126. Kaklamanis L, Leek R, Koukourakis M, Gatter KC, Harris AL. Loss of transporter in antigen processing 1 transport protein and major histocom-patibility complex class I molecules in metastatic versus primary breast cancer. Cancer Res. 1995;55(22):5191-5194.
127. Vitale M, Rezzani R, Rodella L, et al. HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2) down-regulation in high-grade primary breast carcinoma lesions. Cancer Res. 1998;58(4):737-742.
128. Cromme F V, Airey J, Heemels MT, et al. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J Exp Med. 1994;179(1):335-340.
129. Fowler NL, Frazer IH. Mutations in TAP genes are common in cervical carcinomas. Gynecol Oncol. 2004;92(3):914-921.
130. Ritz U, Momburg F, Pilch H, Huber C, Maeurer MJ, Seliger B. Deficient expression of components of the MHC class I antigen processing machinery in human cervical carcinoma. Int J Oncol. 2001;19(6):1211-1220.
131. Dissemond J, Gotte P, Mors J, et al. Association of TAP1 downregulation in human primary melanoma lesions with lack of spontaneous regression. Melanoma Res. 2003;13(3):253-258.
132. Seliger B, Ritz U, Abele R, et al. Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. Cancer Res. 2001;61(24):8647-8650.
133. Yang T, McNally BA, Ferrone S, Liu Y, Zheng P. A single-nucleotide deletion leads to rapid degradation of TAP-1 mRNA in a melanoma cell line. J Biol Chem. 2003;278(17):15291-15296.
134. Facoetti A, Nano R, Zelini P, et al. Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors. Clin Cancer Res. 2005;11(23):8304-8311.
135. Ayalon O, Hughes EA, Cresswell P, et al. Induction of transporter associated with antigen processing by interferon gamma confers endothelial cell cytoprotection against natural killer-mediated lysis. Proc Natl Acad Sci USA. 1998;95(5):2435-2440.
136. Ma W, Lehner PJ, Cresswell P, Pober JS, Johnson DR. Interferon-gamma rapidly increases peptide transporter (TAP) subunit expression and peptide transport capacity in endothelial cells. J Biol Chem. 1997;272(26):16585-16590.
137. Mehta AM, Jordanova ES, Corver WE, et al. Single nucleotide polymorphisms in antigen processing machinery component ERAP1 significantly associate with clinical outcome in cervical carcinoma. Genes Chromosomes Cancer. 2009;48(5):410-418.
138. Chen HL, Gabrilovich D, Tampe R, Girgis KR, Nadaf S, Carbone D P. A functionally defective allele of TAP1 results in loss of MHC class I antigen presentation in a human lung cancer. Nat Genet. 1996;13(2):210-213.
139. Seliger B, Ritz U, Abele R, et al. Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. Cancer Res. 2001;61(24):8647-8650.
140. Fruci D, Giacomini P, Nicotra MR, et al. Altered expression of endoplas-mic reticulum aminopeptidases ERAP1 and ERAP2 in transformed non-lymphoid human tissues. J Cell Physiol. 2008;216(3):742-749.
141. Kamphausen E, Kellert C, Abbas T, et al. Distinct molecular mechanisms leading to deficient expression of ER-resident aminopeptidases in melanoma. Cancer Immunol Immunother. 2010;59(8):1273-1284.
142. Ogino T, Bandoh N, Hayashi T, Miyokawa N, Harabuchi Y, Ferrone S. Association of tapasin and HLA class I antigen down-regulation in primary maxillary sinus squamous cell carcinoma lesions with reduced survival of patients. Clin Cancer Res. 2003;9(11):4043-4051.
143. Seliger B, Schreiber K, Delp K, et al. Downregulation of the constitutive tapasin expression in human tumor cells of distinct origin and its transcrip-tional upregulation by cytokines. Tissue Antigens. 2001;57(1):39-45.
144. Jiang Q, Pan HY, Ye DX, Zhang P, Zhong L P, Zhang ZY. Downregulation of tapasin expression in primary human oral squamous cell carcinoma: association with clinical outcome. Tumour Biol. 2010;31(5):451-459.
145. Han LY, Fletcher MS, Urbauer DL, et al. HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma. Clin Cancer Res. 2008;14(11):3372- 3379.
146. Leys CM, Nomura S, LaFleur BJ, et al. Expression and prognostic significance of prothymosin-alpha and ERp57 in human gastric cancer. Surgery. 2007;141(1):41-50.
147. Bukur J, Herrmann F, Handke D, Recktenwald C, Seliger B. Identification of E2F1 as an important transcription factor for the regulation of tapasin expression. J Biol Chem. 2010;285(40):30419-30426.
148. Aultman D, Adamashvili I, Yaturu K, et al. Soluble HLA in human body fluids. Hum Immunol. 1999;60(3):239-244.
149. Puppo F, Scudeletti M, Indiveri F, Ferrone S. Serum HLA class I antigens: markers and modulators of an immune response? Immunol Today. 1995;16(3):124-127.
150. Puppo F, Indiveri F, Scudeletti M, Ferrone S. Soluble HLA antigens: new roles and uses. Immunol Today. 1997;18(4):154-155.
151. Tabayoyong WB, Zavazava N. Soluble HLA revisited. Leuk Res. 2007;31(2):121-125.
152. Krangel MS. Secretion of HLA-A and-B antigens via an alternative RNA splicing pathway. J Exp Med. 1986;163(5):1173-1190.
153. Demaria S, Schwab R, Gottesman SR, Bushkin Y. Soluble beta 2-microglob-ulin-free class I heavy chains are released from the surface of activated and leukemia cells by a metalloprotease. J Biol Chem. 1994;269(9):6689-6694.
154. Demaria S, Bushkin Y. Soluble HLA proteins with bound peptides are released from the cell surface by the membrane metalloproteinase. Hum Immunol. 2000;61(12):1332-1338.
155. Albitar M, Vose JM, Johnson MM, et al. Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease. Leuk Res. 2007;31(2):139-145.
156. Bangia N, Ferrone S. Antigen presentation machinery (APM) modulation and soluble HLA molecules in the tumor microenvironment: do they provide tumor cells with escape mechanisms from recognition by cytotoxic T lymphocytes? Immunol Invest. 2006;35(3-4):485-503.
157. Dobbe LM, Stam NJ, Neefjes JJ, Giphart MJ. Biochemical complexity of serum HLA class I molecules. Immunogenetics. 1988;27(3):203-210.
158. Perosa F, Luccarelli G, Prete M, Ferrone S, Dammacco F. Increased serum levels of beta2m-free HLA class I heavy chain in multiple myeloma. Br J Haematol. 1999;106(4):987-994.
159. Perosa F, Prete M, Luccarelli G, Dammacco F. Size variants of beta-2-mi-croglobulin-free human leucocyte antigen class I heavy chain make different contributions to its serum increase in multiple myeloma. Br J Haematol. 2003;120(1):36-43.
160. Cabrera T, Lopez-Nevot MA, Gaforio JJ, Ruiz-Cabello F, Garrido F. Analysis of HLA expression in human tumor tissues. Cancer Immunol Immunother. 2003;52(1):1-9.
161. Garrido F, Algarra I. MHC antigens and tumor escape from immune surveillance. Adv Cancer Res. 2001;83:117-158.
162. Bicknell DC, Kaklamanis L, Hampson R, Bodmer WF, Karran P. Selection for beta 2-microglobulin mutation in mismatch repair-defective colorectal carcinomas. Curr Biol. 1996;6(12):1695-1697.
163. Cabrera T, Collado A, Fernandez MA, et al. High frequency of altered HLA class I phenotypes in invasive colorectal carcinomas. Tissue Antigens. 1998;52(2):114-123.
164. Cabrera T, Maleno I, Collado A, Lopez Nevot MA, Tait BD, Garrido F. Analysis of HLA class I alterations in tumors: choosing a strategy based on known patterns of underlying molecular mechanisms. Tissue Antigens. 2007;69(Suppl 1):264-268.
165. Yamamoto H, Perez-Piteira J, Yoshida T, et al. Gastric cancers of the microsatellite mutator phenotype display characteristic genetic and clinical features. Gastroenterology. 1999;116(6):1348-1357.
166. Benitez R, Godelaine D, Lopez-Nevot MA, et al. Mutations of the beta2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides. Tissue Antigens. 1998;52(6):520-529.
167. Hicklin DJ, Wang Z, Arienti F, Rivoltini L, Parmiani G, Ferrone S. beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma. J Clin Invest. 1998;101(12):2720-2729.
168. Serrano A, Tanzarella S, Lionello I, et al. Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2'-deoxycytidine treatment. Int J Cancer. 2001;94(2):243-251.
169. White CA, Thomson SA, Cooper L, et al. Constitutive transduction of peptide transporter and HLA genes restores antigen processing function and cytotoxic T cell-mediated immune recognition of human melanoma cells. Int J Cancer. 1998;75(4):590-595.
170. Tang Q, Zhang J, Qi B, Shen C, Xie W. Downregulation of HLA class I molecules in primary oral squamous cell carcinomas and cell lines. Arch Med Res. 2009;40(4):256-263.
171. Maleno I, Lopez-Nevot MA, Cabrera T, Salinero J, Garrido F. Multiple mechanisms generate HLA class I altered phenotypes in laryngeal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Cancer Immunol Immunother. 2002;51(7):389-396.
172. Cabrera T, Angustias FM, Sierra A, et al. High frequency of altered HLA class I phenotypes in invasive breast carcinomas. Hum Immunol. 1996;50(2):127-134.
173. Garrido F, Ruiz-Cabello F, Cabrera T, et al. Implications for immunosur-veillance of altered HLA class I phenotypes in human tumours. Immunol Today. 1997;18(2):89-95.
174. Soong TW, Hui KM. Locus-specific transcriptional control of HLA genes. J Immunol. 1992;149(6):2008-2020.
175. Soong TW, Hui KM. Regulation of the expression of major histocompat-ibility complex class I genes in human colorectal cancer. Cancer Detect Prev. 1991;15(3):231-239.
176. Cabrera T, Salinero J, Fernandez MA, Garrido A, Esquivias J, Garrido F. High frequency of altered HLA class I phenotypes in laryngeal carcinomas. Hum Immunol. 2000;61(5):499-506.
177. Griffioen M, Ouwerkerk IJ, Harten V, Schrier PI. HLA-B locus-specific downregulation in human melanoma requires enhancer A as well as a sequence element located downstream of the transcription initiation site. Immunogenetics. 2000;52(1-2):121-128.
178. Ashrafi GH, Tsirimonaki E, Marchetti B, et al. Down-regulation of MHC class I by bovine papillomavirus E5 oncoproteins. Oncogene. 2002;21(2):248-259.
179. Griffioen M, Peltenburg LT, van Oorschot DA, Schrier PI. C-myc represses transiently transfected HLA class I promoter sequences not locus-specifically. Immunobiology. 1995;193(2-4):238-47.
180. Herrmann F, Lehr HA, Drexler I, et al. HER-2/neu-mediated regulation of components of the MHC class I antigen-processing pathway. Cancer Res. 2004;64(1):215-220.
181. Seliger B, Harders C, Lohmann S, et al. Down-regulation of the MHC class I antigen-processing machinery after oncogenic transformation of murine fibroblasts. Eur J Immunol. 1998;28(1):122-133.
182. Vertegaal AC, Kuiperij HB, Houweling A, Verlaan M, van der Eb AJ, Zantema A. Differential expression of tapasin and immunoproteasome subunits in adenovirus type 5-versus type 12-transformed cells. J Biol Chem. 2003;278(1):139-46.
183. Seliger B. Molecular mechanisms of MHC class I abnormalities and APM components in human tumors. Cancer Immunol Immunother. 2008;57(11):1719-1726.
184. Feenstra M, Verdaasdonk M, van der Zwan AW, de WR, Slootweg P, Tilanus M. Microsatellite analysis of microdissected tumor cells and 6p high density microsatellite analysis in head and neck squamous cell carcinomas with down-regulated human leukocyte antigen class I expression. Lab Invest. 2000;80(3):405-414.
185. Torres MJ, Ruiz-Cabello F, Skoudy A, et al. Loss of an HLA haplotype in pancreas cancer tissue and its corresponding tumor derived cell line. Tissue Antigens. 1996;47(5):372-381.
186. Shimura T, Hagihara M, Yamamoto K, et al. Quantification of serum-soluble HLA class I antigens in patients with gastric cancer. Hum Immunol. 1994;40(3):183-186.
187. Westhoff U, Fox C, Otto FJ. Soluble HLA class I antigens in plasma of patients with malignant melanoma. Anticancer Res. 1998;18(5B):3789-3792.
188. Shimura T, Tsutsumi S, Hosouchi Y, et al. Clinical significance of soluble form of HLA class I molecule in Japanese patients with pancreatic cancer. Hum Immunol. 2001;62(6):615-619.
189. Carbone E, Neri P, Mesuraca M, et al. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood. 2005;105(1):251-258.
190. Leleu X, Le FG, Facon T, et al. Total soluble HLA class I and soluble HLA-G in multiple myeloma and monoclonal gammopathy of undetermined significance. Clin Cancer Res. 2005;11(20):7297-7303.
191. Anichini A, Mortarini R, Nonaka D, et al. Association of antigen-processing machinery and HLA antigen phenotype of melanoma cells with survival in American Joint Committee on Cancer stage III and IV melanoma patients. Cancer Res. 2006;66(12):6405-6411.
192. Norell H, Carlsten M, Ohlum T, et al. Frequent loss of HLA-A2 expression in metastasizing ovarian carcinomas associated with genomic haplo-type loss and HLA-A2-restricted HER-2/neu-specific immunity. Cancer Res. 2006;66(12):6387- 6394.
193. Germain RN, Margulies DH. The biochemistry and cell biology of antigen processing and presentation. Annu Rev Immunol. 1993;11:403-450.
194. Cerundolo V, de la SH. Description of HLA class I-and CD8-deficient patients: Insights into the function of cytotoxic T lymphocytes and NK cells in host defense. Semin Immunol. 2006;18(6):330-336.
195. Shrestha D, Szollosi J, Jenei A. Bare lymphocyte syndrome: an opportunity to discover our immune system. Immunol Lett. 2012;141(2):147-157.
196. Gadola SD, Moins-Teisserenc HT, Trowsdale J, Gross WL, Cerundolo V. TAP deficiency syndrome. Clin Exp Immunol. 2000;121(2):173-178.
197. de la SH, Houssaint E, Peyrat MA, et al. Human peptide transporter deficiency: importance of HLA-B in the presentation of TAP-independent EBV antigens. J Immunol. 1997;158(10):4555-4563.
198. Vugmeyster Y, Glas R, Perarnau B, Lemonnier FA, Eisen H, Ploegh H. Major histocompatibility complex (MHC) class I KbDb-/-deficient mice possess functional CD8+ T cells and natural killer cells. Proc Natl Acad Sci USA. 1998;95(21):12492-12497.
199. Zimmer J, Donato L, Hanau D, et al. Activity and phenotype of natural killer cells in peptide transporter (TAP)-deficient patients (type I bare lymphocyte syndrome). J Exp Med. 1998;187(1):117-122.
200. van der Bruggen P, van den Eynde BJ. Processing and presentation of tumor antigens and vaccination strategies. Curr Opin Immunol. 2006;18(1):98-104.
201. Campoli M, Ferrone S. Tumor escape mechanisms: potential role of soluble HLA antigens and NK cells activating ligands. Tissue Antigens. 2008;72(4):321-334.
202. Contini P, Ghio M, Merlo A, et al. Soluble HLA class I/CD8 ligation triggers apoptosis in EBV-specific CD8+ cytotoxic T lymphocytes by Fas/Fas-ligand interaction. Hum Immunol. 2000;61(12):1347-1351.
203. Contini P, Ghio M, Poggi A, et al. Soluble HLA-A,-B,-C and-G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation. Eur J Immunol. 2003;33(1):125-134.
204. Puppo F, Contini P, Ghio M, et al. Soluble human MHC class I molecules induce soluble Fas ligand secretion and trigger apoptosis in activated CD8(+) Fas (CD95)(+) T lymphocytes. Int Immunol. 2000;12(2):195-203.
205. Zavazava N, Kronke M. Soluble HLA class I molecules induce apoptosis in alloreactive cytotoxic T lymphocytes. Nat Med. 1996;2(9):1005-1010.
206. Goldberg J, Shrikant P, Mescher M F. In vivo augmentation of tumor-specific CTL responses by class I/peptide antigen complexes on microspheres (large multivalent immunogen). J Immunol. 2003;170(1):228-235.
207. O'Herrin SM, Slansky JE, Tang Q, et al. Antigen-specific blockade of T cells in vivo using dimeric MHC peptide. J Immunol. 2001;167(5):2555-2560.
208. Costello RT, Sivori S, Marcenaro E, et al. Defective expression and function of natural killer cell-triggering receptors in patients with acute mye-loid leukemia. Blood. 2002;99(10):3661-3667.
209. Pierson BA, Miller JS. CD56+bright and CD56+dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis. Blood. 1996;88(6):2279- 2287.